Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KA3 | P51812 | 19/20 | 0.64 |
| ▸ | RPS6KA2 | Q15349 | 3/20 | 0.55 |
| ▸ | RPS6KA1 | Q15418 | 1/20 | 0.55 |
| ▸ | RPS6KA6 | Q9UK32 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1982846 | 1.00 | RPS6KA3 (0.64) | RPS6KA3RPS6KA2RPS6KA1RPS6KA6 | |
| SCHEMBL1982725 | 1.00 | RPS6KA3 (0.64) | RPS6KA3RPS6KA2RPS6KA1RPS6KA6 | |
| SCHEMBL30137600 | 0.90 | RPS6KA3 (0.64) | RPS6KA3RPS6KA2RPS6KA1RPS6KA6 | |
| SCHEMBL1984265 | 0.88 | RPS6KA3 (0.66) | RPS6KA3 | |
| SCHEMBL30137612 | 0.87 | RPS6KA3 (0.64) | RPS6KA3RPS6KA2RPS6KA1RPS6KA6 | |
| SCHEMBL30137580 | 0.87 | RPS6KA3 (0.64) | RPS6KA3RPS6KA2RPS6KA1RPS6KA6 | |
| SCHEMBL1990125 | 0.84 | RPS6KA3 (0.61) | RPS6KA3RPS6KA2RPS6KA1RPS6KA6 | |
| SCHEMBL14973201 | 0.81 | RPS6KA3 (0.64) | RPS6KA3RPS6KA2 | |
| SCHEMBL14973203 | 0.81 | RPS6KA3 (0.64) | RPS6KA3RPS6KA2 | |
| SCHEMBL1985848 | 0.81 | RPS6KA3 (0.64) | RPS6KA3RPS6KA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115611897-A | Compounds as RSK2 inhibitors and uses thereof | 南京圣和药业股份有限公司 | 2023-01-17 | — | — | CN | disclosed |
| CN-113620950-A | Carboxamide derivatives useful as RSK inhibitors | 凤凰分子设计公司 | 2021-11-09 | — | — | CN | disclosed |
| CN-109071542-B | Carboxamide derivatives useful as RSK inhibitors | 凤凰分子设计公司 | 2021-07-20 | — | — | CN | disclosed |
| EP-3848373-A1 | N-(1-((HETEROCYCLYL)METHYL)-1H-PYRAZOL-4-YL)-6-OXO-6,7,8,9- TETRAHYDROPYRIDO[3',2':4,5]PYRROLO[L,2-A]PYRAZINE-2-CARBOXAMIDE DERIVATIVES AS P90 RIBOSOMAL S6 KINASE (RSK) INHIBITORS FOR TREATING CANCER | Phoenix Molecular Designs (CA) | 2021-07-14 | — | — | EP | disclosed |
| US-20210186961-A1 | CARBOXAMIDE DERIVATIVES USEFUL AS RSK INHIBITORS | PHOENIX MOLECULAR DESIGNS (CA) | 2021-06-24 | — | — | US | disclosed |
| US-20210186961-A1 | CARBOXAMIDE DERIVATIVES USEFUL AS RSK INHIBITORS | PHOENIX MOLECULAR DESIGNS (CA) | 2021-06-24 | — | — | US | disclosed |
| EP-3416964-B1 | 6-OXO-N-(1-(BENZYL)-1H-PYRAZOL-4-YL)-6,7,8,9- TETRAHYDROPYRIDO[3',2':4,5]PYRROLO[1,2-A]PYRAZINE-2-CARBOXAMIDE DERIVATIVES AS P90 RIBOSOMAL S6 KINASE (RSK) INHIBITORS FOR TREATING CANCER | PHOENIX MOLECULAR DESIGNS (CA) | 2020-12-16 | — | — | EP | disclosed |
| EP-3416964-B1 | 6-OXO-N-(1-(BENZYL)-1H-PYRAZOL-4-YL)-6,7,8,9- TETRAHYDROPYRIDO[3',2':4,5]PYRROLO[1,2-A]PYRAZINE-2-CARBOXAMIDE DERIVATIVES AS P90 RIBOSOMAL S6 KINASE (RSK) INHIBITORS FOR TREATING CANCER | PHOENIX MOLECULAR DESIGNS (CA) | 2020-12-16 | — | — | EP | disclosed |
| US-10758530-B2 | Carboxamide derivatives useful as rsk inhibitors | PHOENIX MOLECULAR DESIGNS (CA) | 2020-09-01 | — | — | US | disclosed |
| US-10758530-B2 | Carboxamide derivatives useful as rsk inhibitors | PHOENIX MOLECULAR DESIGNS (CA) | 2020-09-01 | — | — | US | disclosed |
| EP-2509979-B1 | HETEROCYCLIC COMPOUNDS CONTAINING A PYRROLOPYRIDINE OR BENZIMIDAZOLE CORE | BOEHRINGER INGELHEIM INT (DE) | 2016-05-25 | — | — | EP | disclosed |
| US-9073926-B2 | Heterocyclic compounds containing a pyrrolopyridine or benzimidazole core | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-07-07 | — | — | US | disclosed |
| US-9073926-B2 | Heterocyclic compounds containing a pyrrolopyridine or benzimidazole core | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-07-07 | — | — | US | disclosed |
| US-9073926-B2 | Heterocyclic compounds containing a pyrrolopyridine or benzimidazole core | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-07-07 | — | — | US | disclosed |
| US-20130137680-A1 | HETEROCYCLIC COMPOUNDS CONTAINING A PYRROLOPYRIDINE OR BENZIMIDAZOLE CORE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-05-30 | — | — | US | disclosed |
| US-20130137680-A1 | HETEROCYCLIC COMPOUNDS CONTAINING A PYRROLOPYRIDINE OR BENZIMIDAZOLE CORE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-05-30 | — | — | US | disclosed |
| US-20130137680-A1 | HETEROCYCLIC COMPOUNDS CONTAINING A PYRROLOPYRIDINE OR BENZIMIDAZOLE CORE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-05-30 | — | — | US | disclosed |
| EP-2509979-A1 | HETEROCYCLIC COMPOUNDS CONTAINING A PYRROLOPYRIDINE OR BENZIMIDAZOLE CORE | Boehringer Ingelheim International GmbH (DE) | 2012-10-17 | — | — | EP | disclosed |
| WO-2011071725-A1 | HETEROCYCLIC COMPOUNDS CONTAINING A PYRROLOPYRIDINE OR BENZIMIDAZOLE CORE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-06-16 | — | — | WO | disclosed |
| WO-2011071725-A1 | HETEROCYCLIC COMPOUNDS CONTAINING A PYRROLOPYRIDINE OR BENZIMIDAZOLE CORE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10758530-B2 | Carboxamide derivatives useful as rsk inhibitors | RPS6KA5, RPS6KA2, RPS6KA1 | RPS6KA3 4/4885RPS6KA2 2/4885RPS6KA1 3/4885 |
| US-20210186961-A1 | CARBOXAMIDE DERIVATIVES USEFUL AS RSK INHIBITORS | RPS6KA2, RPS6KA5, RPS6KA1 | RPS6KA3 4/4885RPS6KA2 1/4885RPS6KA1 3/4885 |
| US-20130137680-A1 | HETEROCYCLIC COMPOUNDS CONTAINING A PYRROLOPYRIDINE OR BENZIMIDAZOLE CORE | PKD1, PAH, JAK2 | RPS6KA3 955/4885RPS6KA2 1164/4885RPS6KA1 900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.